Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 23, 2020
Reporting Period: Single event date (April 23, 2020)
This filing reports a specific corporate event under Item 8.01 (Other Events) and does not cover a standard financial reporting period (e.g., quarterly or annual).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a scientific publication and does not contain financial statements or operational metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document focuses solely on the announcement of a scientific review publication.
Outlook, Commentary, and Risks
Management Commentary and Events:
- The Company announced the publication of an invited review titled "Tumor Necrosis Factor a Blockade: an Opportunity to Tackle Breast Cancer."
- The review was published in Frontiers in Oncology.
- The author is Dr. Roxana Schillaci from the Lab of Molecular Mechanisms, Instituto de Biología y Medicina Experimental-CONICET, Argentina.
- The filing text does not provide specific risk factors or contingencies related to this event.
- None reported.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on the scientific review.
- Confirm the publication status and date in Frontiers in Oncology.
- Review the Company's recent financial filings (10-K or 10-Q) for actual financial performance data, as this 8-K contains none.